Drugs / HIB210
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05928585 | Jul 2023 → Jun 2024 | immune system disorder | HI-Bio, A Biogen Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HIB210 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05928585 ↗ |
| Modality | Monoclonal antibody | “Experimental monoclonal antibody” NCT05928585 ↗ |